Latest Careteq (ASX:CTQ) News

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

Careteq Limited has successfully raised $2.2 million through a two-tranche share placement, with a significant portion subject to upcoming shareholder approval. The funds aim to support project acquisitions, debt reduction, and working capital needs.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Careteq Limited has agreed to sell its Embedded Health Solutions business for $5 million, aiming to strengthen its balance sheet and focus on expanding its home medication review platform amid ongoing tax disputes.

Careteq Limited reported a disciplined operating cash flow in Q2 FY26 with strong growth in its Embedded Health Solutions segment and ongoing resolution of an ATO tax incentive dispute.

Careteq Limited signals progress on its 1-System platform integration with a planned Q3 FY26 restart, while Embedded Health Solutions expands aged care contracts and the company navigates a significant ATO R&D tax objection.

Careteq Limited has returned to profitability in FY25, reporting a 5.4% revenue increase and a 171% jump in underlying EBITDA, driven by strategic divestments and acquisitions.

Careteq Limited reported a dramatic reduction in its FY25 loss to just $72,204, down from $2.67 million the prior year, while facing a significant $3.6 million dispute with the Australian Taxation Office over R&D tax claims.

Careteq Limited reports a significant reduction in operating cash outflow and modest revenue growth for FY25, while facing delays in its key platform integration and a dispute with the ATO over R&D claims.

Careteq Limited has raised $625,000 through a convertible note from investor Antanas Guoga and loans from its board, strengthening its working capital position for the medium term.